2019年新型冠状病毒肺炎治疗现状

Q4 Immunology and Microbiology

中华微生物学和免疫学杂志 Pub Date : 2020-01-31 DOI:10.3760/CMA.J.ISSN.0254-5101.2020.01.002

Zhu Naiwei, P. Zhao, Z. Qi

{"title":"2019年新型冠状病毒肺炎治疗现状","authors":"Zhu Naiwei, P. Zhao, Z. Qi","doi":"10.3760/CMA.J.ISSN.0254-5101.2020.01.002","DOIUrl":null,"url":null,"abstract":"2019 novel coronavirus (2019-nCoV) is a new member of coronavirus family that can cause serious respiratory diseases after the emergence of severe acute respiratory syndrome-coronavirus (SARS-CoV) and middle east respiratory syndrome-coronavirus (MERS-CoV). At present, there is no specific antiviral drug targeting 2019-nCoV. In facing of the increasingly serious epidemic of 2019 novel coronavirus pneumonia and the urgent needs in drug treatment strategies, this paper reviewed the current research situation and progress in antiviral treatment for the newly identified disease. \n \nKey words: \n2019 novel coronavirus; Treatment; Drugs","PeriodicalId":10089,"journal":{"name":"中华微生物学和免疫学杂志","volume":"40 1","pages":"7-10"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Current status of treatment for 2019 novel coronavirus pneumonia\",\"authors\":\"Zhu Naiwei, P. Zhao, Z. Qi\",\"doi\":\"10.3760/CMA.J.ISSN.0254-5101.2020.01.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"2019 novel coronavirus (2019-nCoV) is a new member of coronavirus family that can cause serious respiratory diseases after the emergence of severe acute respiratory syndrome-coronavirus (SARS-CoV) and middle east respiratory syndrome-coronavirus (MERS-CoV). At present, there is no specific antiviral drug targeting 2019-nCoV. In facing of the increasingly serious epidemic of 2019 novel coronavirus pneumonia and the urgent needs in drug treatment strategies, this paper reviewed the current research situation and progress in antiviral treatment for the newly identified disease. \\n \\nKey words: \\n2019 novel coronavirus; Treatment; Drugs\",\"PeriodicalId\":10089,\"journal\":{\"name\":\"中华微生物学和免疫学杂志\",\"volume\":\"40 1\",\"pages\":\"7-10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华微生物学和免疫学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.0254-5101.2020.01.002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华微生物学和免疫学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.0254-5101.2020.01.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 2

摘要

2019新型冠状病毒（2019-nCoV）是继严重急性呼吸综合征冠状病毒（SARS-CoV）和中东呼吸综合征病毒（MERS-CoV。目前尚无针对2019-nCoV的特效抗病毒药物。面对2019年新型冠状病毒肺炎疫情的日益严重和药物治疗策略的迫切需要，本文综述了新发现疾病抗病毒治疗的研究现状和进展。关键词：2019新型冠状病毒；治疗；药物

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Current status of treatment for 2019 novel coronavirus pneumonia

2019 novel coronavirus (2019-nCoV) is a new member of coronavirus family that can cause serious respiratory diseases after the emergence of severe acute respiratory syndrome-coronavirus (SARS-CoV) and middle east respiratory syndrome-coronavirus (MERS-CoV). At present, there is no specific antiviral drug targeting 2019-nCoV. In facing of the increasingly serious epidemic of 2019 novel coronavirus pneumonia and the urgent needs in drug treatment strategies, this paper reviewed the current research situation and progress in antiviral treatment for the newly identified disease. Key words: 2019 novel coronavirus; Treatment; Drugs

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华微生物学和免疫学杂志 Immunology and Microbiology-Virology

CiteScore

0.50

自引率

0.00%

发文量

6906

期刊介绍： Chinese Journal of Microbiology and Immunology established in 1981. It is one of the series of journal sponsored by Chinese Medical Association. The aim of this journal is to spread and exchange the scientific achievements and practical experience in order to promote the development of medical microbiology and immunology. Its main contents comprise academic thesis, brief reports, reviews, summaries, news of meetings, book reviews and trends of home and abroad in this field. The distinguishing feature of the journal is to give the priority to the reports on the research of basic theory, and take account of the reports on clinical and practical skills.